Univar Inc. (NYSE: UNVR) has not been public that long, and now we have seen more analysts chime in after the company’s first formal earnings report as a public company. For those who do not know Univar, it is a distributor of specialty and basic chemicals from more than 8,000 producers – and it has over 800 distribution facilities throughout North America, Western Europe, the Asia-Pacific region, and Latin America.

This was considered to be a relatively hot IPO at the time.

Univar completed its IPO in June at a price of $22.00 per share. Its underwriters for the IPO exercised in full their option to purchase an additional 5,250,000 shares of common stock from certain stockholders. As a result, some 20,000,000 shares of common stock were sold by the company itself and some 20,250,000 shares were sold by stockholders in the IPO. Univar also completed a concurrent private placement of $350 million of shares of common stock to Dahlia Investments Pte. Ltd., an indirect wholly owned subsidiary of Temasek Holdings.

Here is how the underwriters have issued coverage:

• Deutsche Bank – Hold with a $24.50 target;
• Goldman Sachs – Buy with a $31 target;
• BofA Merrill Lynch – n/a
• Barclays – n/a
• Credit Suisse – Neutral with a $25 target;
• J.P. Morgan – n/a
• Jefferies – Buy with a $29 target;
• Morgan Stanley – n/a

Also, SunTrust Robinson Humphrey started Univar at Neutral with a $27 target. Wells Fargo also assigned a new Market perform rating. William Blair assigned a Market Perform rating.

Univar shares were up 2.25% at $22.63 on Thursday morning. The post-IPO range is $21.41 to $27.75.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.